Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Rocky Lee Baker

TitleAsst Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-IMM MICRO GENERAL OPER
Phone303/724-9373

    Collapse Research 
    Collapse research activities and funding
    R21AI133059     (BAKER, ROCKY LEE)Jan 1, 2018 - Dec 31, 2019
    NIH/NIAID
    T cells reactive to Hybrid Insulin Peptides (HIPs) as biomarkers in autoimmune diabetes
    Role: Principal Investigator

    R01AI146202     (BAKER, ROCKY LEE)Jun 2, 2020 - May 31, 2025
    NIH/NIAID
    Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Human Type 1 Diabetes
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Arribas-Layton D, Guyer P, Delong T, Dang M, Chow IT, Speake C, Greenbaum CJ, Kwok WW, Baker RL, Haskins K, James EA. Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01. Diabetes. 2020 Jul; 69(7):1492-1502. PMID: 32291282.
      View in: PubMed
    2. Baker RL, Jamison BL, Haskins K. Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2019 08; 26(4):195-200. PMID: 31166225.
      View in: PubMed
    3. Baker RL, Rihanek M, Hohenstein AC, Nakayama M, Michels A, Gottlieb PA, Haskins K, Delong T. Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1830-1840. PMID: 31175101.
      View in: PubMed
    4. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, Haskins K. Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells. J Immunol. 2019 07 01; 203(1):48-57. PMID: 31109955.
      View in: PubMed
    5. Dirice E, Kahraman S, De Jesus DF, El Ouaamari A, Basile G, Baker RL, Yigit B, Piehowski PD, Kim MJ, Dwyer AJ, Ng RWS, Schuster C, Vethe H, Martinov T, Ishikawa Y, Teo AKK, Smith RD, Hu J, Haskins K, Serwold T, Qian WJ, Fife BT, Kissler S, Kulkarni RN. Increased ß-cell proliferation before immune cell invasion prevents progression of type 1 diabetes. Nat Metab. 2019 May; 1(5):509-518. PMID: 31423480.
      View in: PubMed
    6. Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, Delong T, Friedman RS, Nakayama M, Haskins K. CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse. Diabetes. 2018 09; 67(9):1836-1846. PMID: 29976617.
      View in: PubMed
    7. Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017 03; 78:11-18. PMID: 27802879.
      View in: PubMed
    8. Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, Armstrong M, Powell RL, Reisdorph N, Kumar N, Elso CM, DeNicola M, Bottino R, Powers AC, Harlan DM, Kent SC, Mannering SI, Haskins K. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016 Feb 12; 351(6274):711-4. PMID: 26912858.
      View in: PubMed
    9. Baker RL, Bradley B, Wiles TA, Lindsay RS, Barbour G, Delong T, Friedman RS, Haskins K. Cutting Edge: Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes. J Immunol. 2016 Jan 01; 196(1):39-43. PMID: 26608914.
      View in: PubMed
    10. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, Rewers MR, Michels A, Haskins K. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2014 May; 50:38-41. PMID: 24239002.
      View in: PubMed
    11. Baker RL, Delong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. J Immunol. 2013 Oct 15; 191(8):3990-4. PMID: 24043895.
      View in: PubMed
    12. Delong T, Baker RL, He J, Haskins K. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunol Res. 2013 Mar; 55(1-3):167-72. PMID: 22971988.
      View in: PubMed
    13. Delong T, Baker RL, He J, Barbour G, Bradley B, Haskins K. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes. 2012 Dec; 61(12):3239-46. PMID: 22912420.
      View in: PubMed
    14. Baker RL, Mallevaey T, Gapin L, Haskins K. T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes. Eur J Immunol. 2012 Mar; 42(3):672-80. PMID: 22488364.
      View in: PubMed
    15. Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Barbour G, Bradley B, Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes. 2011 Sep; 60(9):2325-30. PMID: 21734016.
      View in: PubMed
    16. Baker RL, Wagner DH, Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun. 2008 Dec; 31(4):385-92. PMID: 18951762.
      View in: PubMed
    Baker's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2020 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)